Video

A Cardiologist’s Approach to Followup For Patients on ADT and Strategies in Multidisciplinary Care

Cardiologist Anees A. Daud, MD, highlights how a cardiologist may followup with patients receiving androgen deprivation therapy and how multidisciplinary care plays a role in this setting.

January 2023 AbbVie Inc. Company Confidential

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Laura Davis, MD, on persistent poverty and early onset prostate cancer
Laura Davis, MD, on persistent poverty and early onset prostate cancer
Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
Ruben Olivares, MD, answers a question during a Zoom video interview
Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Post-RP incontinence: Low procedure rates examined
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Data link incontinence severity to post-radical prostatectomy care
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Expert discusses differentiating prostate cancer from age-related issues
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Related Content
Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC
July 2nd 2025

Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC

Hannah Clarke
The study will utilize the companion lipid biomarker test, PCPro, to identify patients who may benefit from the addition of opaganib to darolutamide.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
FDA updates in urology: June 2025
July 1st 2025

FDA updates in urology: June 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from June 2025.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Conceptual image for viral ethiology of prostate cancer. 3D illustration showing Human Papilloma Viruses HPV infecting prostate gland which develops cancerous tumor | Image Credit: © Dr_Microbe - stock.adobe.com
June 27th 2025

Biden’s prostate cancer diagnosis underscores importance of screening, awareness

Hannah Clarke
The unfortunate news of President Biden’s diagnosis has put a spotlight on prostate cancer, offering an opportunity to educate on the risks of the disease and the benefits of screening.
Colorful DNA molecule. Concept image of a structure of the genetic code. | Image Credit: © ktsdesign - stock.adobe.com
June 26th 2025

Genomic test can predict resistance to chemotherapy in prostate cancer

Hannah Clarke
The test utilizes chromosomal instability signatures to predict resistance to taxane-based chemotherapy in metastatic prostate cancer.
© 2025 MJH Life Sciences

All rights reserved.